SCHEMBL7192887

SCHEMBL7192887

COC(=O)C1CSC(c2cc(O)ccc2O)N1C(C)=O

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.44
▸ GAA P10253 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ ALDH1A1 P00352 2/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ CYP2C19 P33261 2/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ CYP1A2 P05177 1/20 0.41
▸ ACE P12821 2/20 0.37
▸ GFER P55789 1/20 0.36
▸ CA12 O43570 1/20 0.35
▸ CA1 P00915 1/20 0.35
▸ CA2 P00918 1/20 0.35
▸ CA7 P43166 1/20 0.35
▸ CA9 Q16790 1/20 0.35
▸ CA14 Q9ULX7 1/20 0.35
▸ HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7188457 0.87 POLB (0.40) POLBGAARAB9AALDH1A1ACE
SCHEMBL7196787 0.86 POLB (0.46) POLBGAARAB9AALDH1A1MEN1
SCHEMBL7196968 0.86 POLB (0.53) POLBGAARAB9AALDH1A1ACE
SCHEMBL7189420 0.77 SMN1; SMN2 (0.41) POLBGAARAB9AALDH1A1MEN1
SCHEMBL7191146 0.74 POLB (0.46) POLBGAARAB9AALDH1A1MEN1
SCHEMBL7192631 0.74 POLB (0.42) POLBGAARAB9AALDH1A1KMT2A
SCHEMBL7186265 0.74 POLB (0.57) POLBGAARAB9AALDH1A1ACE
SCHEMBL7193645 0.74 POLB (0.51) POLBGAARAB9AALDH1A1ACE
SCHEMBL683185 0.70 ACE (0.76) POLBGAAALDH1A1MEN1KMT2A
SCHEMBL7194189 0.68 ALDH1A1 (0.42) POLBGAAALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030022923-A1 Methods for treatment of sickle cell anemia MEDINOX, INC. 2003-01-30 — — US disclosed
EP-1173174-A4 METHODS FOR TREATMENT OF SICKLE CELL ANEMIA MEDINOX INC (US) 2002-09-18 — — EP disclosed
US-6355661-B1 STABILITY OF ALDEHYDES AND PROTECTED ALDEHYDES MEDINOX, INC. 2002-03-12 — — US disclosed
EP-1173174-A1 METHODS FOR TREATMENT OF SICKLE CELL ANEMIA Medinox, Inc. (US) 2002-01-23 — — EP disclosed
US-6251927-B1 TREATING SICKLE CELL ANEMIA USING PROTECTED FORMS OF ORGANIC ALDEHYDES MEDINOX, INC. 2001-06-26 — — US disclosed
WO-2000062777-A1 METHODS FOR TREATMENT OF SICKLE CELL ANEMIA MEDINOX, INC. (US) 2000-10-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030022923-A1 Methods for treatment of sickle cell anemia SORD, HBG1, HBG2 POLB 1455/4885GAA 73/4885RAB9A 4369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback